US Medicare rejects routine coverage of warfarin genetic testing
This article was originally published in Scrip
Executive Summary
The US Medicare programme is proposing to pay for pharmacogenomic testing to predict a patient's response to warfarin only when conducted as part of an appropriately designed clinical trial.